OncoMatch/Clinical Trials/NCT04807816

Targeting ATR in Soft-tissue Sarcomas

Is NCT04807816 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Association of berzosertib with gemcitabine and Gemcitabine for leiomyosarcoma, adult.

Phase 2RecruitingInstitut BergoniéNCT04807816Data as of May 2026

Treatment: Association of berzosertib with gemcitabine · Gemcitabine — Multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trial to assess the antitumor activity of berzosertib in association with gemcitabine

Check if I qualify

Extracted eligibility criteria

Cancer type

Sarcoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Max 3 prior lines

Cannot have received: Gemcitabine (Gemcitabine)

Previous treatment with Gemcitabine

Cannot have received: ATR inhibitor (berzosertib)

Previous treatment with berzosertib or other ATR inhibitor

Lab requirements

Blood counts

Adequate hematological function

Kidney function

Adequate renal function

Liver function

Adequate hepatic function

Adequate hematological, renal, metabolic and hepatic function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify